Compare UFI & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFI | XBIT |
|---|---|---|
| Founded | 1969 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 69.8M |
| IPO Year | 1994 | 2015 |
| Metric | UFI | XBIT |
|---|---|---|
| Price | $6.29 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 106.2K | 42.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $571,344,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $12.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.96 | $2.09 |
| 52 Week High | $6.76 | $3.61 |
| Indicator | UFI | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 42.22 |
| Support Level | $3.72 | $2.27 |
| Resistance Level | $6.76 | $2.45 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 75.06 | 34.78 |
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.